Ref. | n | Year | Study design | Level of evidence | Comparator | Dose (μg/kg per min) | End-points |
---|---|---|---|---|---|---|---|
[2]a,b | 120 | 2001 | Multicentre, prospective, unblinded, randomized trial | II | Milrinone | 10–20 | Haemodynamic parameters |
[26] | 10 | 2000 | Prospective, blinded, randomized, crossover study | III | Dopamine, dopexamine | 2.7 | Jejunal perfusion |
[30]a | 64 | 2000 | Prospective, blinded, randomized, controlled trial | II | Placebo, ranitidine | 4.0 | pHi |
[31]a | 17 | 1999 | Prospective, blinded, randomized, controlled trial | II | Placebo | 6.0 | Haemodynamic parameters, splanchnic blood flow |
[32]a | 110 | 1999 | Observational study | III | - | 0–40 | Haemodynamic parameters |
[14] | 30 | 1997 | Prospective, blinded, randomized trial | II | Enoximone, epinephrine | 3.0 | IMA graft flow |
[33]a,c | 20 | 1997 | Prospective, unblinded, randomized trial | II | Enoximone | 8.0 | Haemodynamic parameters |
[34]c | 20 | 1997 | Prospective, blinded, randomized trial | II | Enoximone | 5.0 | Haemodynamic parameters |
[35]a,b | 30 | 1996 | Prospective, blinded, randomized trial | II | Enoximone | 10.0 | Haemodynamic parameters |
[36]a,b | 28 | 1995 | Prospective, unblinded, randomized controlled trial | II | Control | 4.4 | Haemodynamic parameters, pHi, ICG Clearance |
[37]a,b | 10 | 1994 | Prospective, blinded, randomized trial | II | Dopexamine | 5.0–10.0 | Haemodynamic parameters |
[18]c | 75 | 1993 | Prospective, blinded, randomized trial | II | Enoximone, dopamine | 5.0 | Haemodynamic parameters |
[38]a,b | 16 | 1993 | Prospective, unblinded, nonrandomized controlled trial | III | Sodium nitroprusside, control | Haemodynamic parameters ICG Clearance | |
[10] | 52 | 1992 | Observational study | III | Epinephrine | 2.5–5.0 | Haemodynamic parameters |
[39]a,b | 30 | 1992 | Prospective, unblinded, randomized trial | II | Amrinone | 5–15 | Haemodynamic parameters |
[40] | 10 | 1992 | Observational study | III | Various dose ratios of dopamine/dobutamine | 0–10.0 | Haemodynamic parameters |
[41]a | 20 | 1990 | Prospective, unblinded, randomized trial | II | Enoximone | 5.0 | Haemodynamic parameters |
[42]a | 20 | 1990 | Prospective, unblinded, randomized trial | II | Enoximone | 10.0 | Haemodynamic parameters |
[43]a,b | 40 | 1990 | Prospective, unblinded, randomized trial | II | Enoximone | 5–7 | Haemodynamic parameters |
[44]a | 50 | 1990 | Prospective, unblinded, randomized trial | II | Enoximone | 5.0 | Haemodynamic parameters |
[11]a | 16 | 1986 | Prospective, unblinded, randomized, trial | II | Epinephrine | 4.8 | Haemodynamic parameters |
[45]a,b | 9 | 1986 | Sequential, cross-over study | III | Dopamine | 5–10.0 | Haemodynamic parameters |
[16] | 20 | 1982 | Prospective, blinded, randomized trial | II | Dopamine | 2.5–10.0 | Haemodynamic parameters |